Sarepta's Study Period Extension May Help Gain DMD Drug Approval in the Long Run

Sarepta Therapeutics Inc. (NASDAQ:SRPT) shares slipped over 2% during early trading hours today. The stock dropped after Jefferies mentioned in a research note that the company has decided to extend its Phase 3 study of exon45/53 from one year to two.

The firm mentioned that the study was stretched out due to the Food and Drug Administration’s (FDA) feedback, along with the management’s lack of confidence that clinical efficacy can be reached in 48 weeks, which has an overall negative readthrough to eteplirsen.

Back to news